To study the short-term and long-term efficacy of radioactive iodine 125 (¹²⁵I) seeds implantation in the treatment of local non-small cell lung cancer (NSCLC).

All 67 patients with local NSCLC admitted to the Fifth People′s Hospital of Wuxi City from January 2015 to January 2018 were selected as the research objects and randomly divided into study group 32 cases and control group 35 cases according to random number table method; The control group was treated with paclitaxel combined with cisplatin for chemotherapy, while the observation group was treated with radioactive ¹²⁵I seed implantation on the basis of the control group, The clinical efficacy, CEA, CYFRA21-1, CA125 and EORTC QLQ-C30 scores were compared between the two groups before and after treatment, and the adverse reactions and The incidence of adverse reactions and short-term and long-term follow-up survival of the two groups were compared.

The ORR of the study group was 81.25%, which was significantly higher than that of the control group (57.14%) (P<0.05). After treatment, CYFRA21-1 and CA125 in the study group were significantly lower than those before treatment and after treatment in the control group (P<0.05); the CEA levels in the two groups after treatment were significantly lower than those before treatment (P<0.05). The body symptom score of the study group after treatment was significantly lower than that before treatment and after treatment in the control group (P<0.05); the overall function and overall health score of the two groups after treatment were significantly higher than those before treatment (P<0.05). The total incidence of adverse reactions in the study group was 53.13%, compared with 37.14% in the control group, the difference was not statistically significant (P>0.05). The half year, one-year and two-year survival rates of the study group were 96.88%, 87.50% and 75.00%, which were significantly higher than those of the control group (82.86%, 65.71% and 48.57%) respectively, and the difference was statistically significant (Log-Rank=5.124, P=0.024).

Radioactive ¹²⁵I seed implantation therapy can significantly improve the short-term and long-term survival rate of patients with local NSCLC, improve the serum tumor markers level of patients, and has good safety and high clinical value.